Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Meteora (MET) fluctuates 63.7% in 24 hours: Trading volume surge and technological breakthrough drive rebound

Meteora (MET) fluctuates 63.7% in 24 hours: Trading volume surge and technological breakthrough drive rebound

Bitget PulseBitget Pulse2026/04/22 16:02
Show original
By:Bitget Pulse

Summary of Volatility

In the past 24 hours, MET price rebounded from a low of $0.1489 to a high of $0.2438, currently quoted at $0.1854, with a volatility of 63.7% and a 24-hour increase of approximately 26-29%. Trading volume surged to $250-270 million, up over 3000% from the previous day, and the market capitalization is around $97 million.

Brief Analysis of Abnormal Movements

- Trading volume surge and technical breakthrough: The price broke through a key resistance level, accompanied by a sharp increase in trading volume from a low point, fueling the rebound.

- Solana ecosystem support: Meteora TVL exceeds $415 million, fee generation is active, but there were no official announcements or whale transactions within the past 24 hours.

Market Perspectives and Outlook

Community sentiment is bullish, with discussions on X platform focusing on the price pump and dominance of long positions. Analysts predict that if the breakout is sustained, MET could rise over 30% further; however, tomorrow (April 23), 7.33M MET (worth about $1.4 million) will be unlocked, which may increase selling pressure, raising the risk of a pullback.

Note: This analysis is automatically generated by AI based on public data and on-chain monitoring and is for informational reference only.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify

In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.

华尔街见闻•2026/11/06 15:01

AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.

华尔街见闻•2026/11/06 13:42
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight

Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.

华尔街见闻•2026/11/06 13:23